Focus: MBX Biosciences is a public biotech company headquartered in Carmel, Indiana, specializing in hormone analogues for rare endocrine diseases. The company operates at a small to mid-cap scale with a focused pipeline in endocrinology and rare disease indications.
Profile data last refreshed 16h ago · AI intelligence enriched 2mo ago
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Best suited for early-stage biotech veterans comfortable with clinical-stage risk and willing to help build a commercial infrastructure from scratch around a rare disease franchise.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MBX Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MBX Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed? - simplywall.st
MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed? simplywall.st
MBX Biosciences (MBX), Why Is It Getting So Much Attention Now? - simplywall.st
MBX Biosciences (MBX), Why Is It Getting So Much Attention Now? simplywall.st
MBX Biosciences doses first patient in pivotal Phase 3 trial of once-weekly canvuparatide - app.dealroom.co
MBX Biosciences doses first patient in pivotal Phase 3 trial of once-weekly canvuparatide app.dealroom.co
About 160 adults will test MBX Biosciences’ once-weekly hormone replacement - Stock Titan
About 160 adults will test MBX Biosciences’ once-weekly hormone replacement Stock Titan
Amylin Analogs and Combination Therapies Clinical Trial - GlobeNewswire
Amylin Analogs and Combination Therapies Clinical Trial GlobeNewswire
8-K Filing: Yarrow Bioscience, Inc. (VYNE) (CIK 0001566044) — FORM 8-K
FORM 8-K
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers.
Discovery and characterization of canvuparatide, a once-weekly parathyroid hormone analog for the treatment of hypoparathyroidism.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo